drugset / Trial / NCT03878888

Exparel Use in Bilateral TAP Blocks for Postoperative Pain Control

NCT03878888 ↗

Phase 4 Completed 52 enrolled St. Luke's Hospital, Pennsylvania
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To determine if Exparel (Liposomal Bupivacaine, an FDA approved drug) use in ultrasound guided Transversus Abdominis Plane (TAP) blocks may reduce opioid requirement use postoperatively, reduce pain scores postoperatively, reduce incidence of nausea in the postop period, and decrease length of hospital stay

Timeline

Start
2019-01-15
Primary completion
2019-07-01
Completion
2019-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 266 mg Other